Recombinant Human EMAP-II/AIMP1 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02254P-100UG
Human EMAP-II on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human EMAP-II/AIMP1 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02254P-100UG
Collections: Other recombinant proteins, Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human EMAP-II/AIMP1 Protein is expressed from E.coli with His tag at the N-Terminus.It contains Ala2-Lys312. |
Purity | > 95% as determined by Tris-Bis PAGE |
Accession | Q12904 |
Target Symbol | EMAP-II/AIMP1 |
Synonyms | EMAP-2; EMAP-II; AIMP1; HLD3; SCYE1; p43 |
Species | Human |
Expression System | E. coli |
Tag | N-His |
Expression Range | Ala2-Lys312 |
Mol. Weight | The protein has a predicted MW of 35.4 kDa. The protein migrates to 40-45 kDa based on Tris-Bis PAGE result. |
Form | Liquid |
Formulation | Supplied as 0.22um filtered solution in 20mM Tris, 500mM NaCl, 10% Glycerol (pH 8.0). |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human EMAP-II, His Tag at 2ug/ml (100ul/well) on the plate. Dose response curve for Anti-EMAP-II Antibody, hFc Tag with the EC50 of 0.21ug/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Valid for 12 months from date of receipt when stored at -80°C.; Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
Shipping | Shipped with dry ice. |
Gene Background | The potent antiangiogenic and proinflammatory protein Endothelial Monocyte Activating Polypeptide II (EMAP II) has been described as a mediator of pulmonary vascular and alveolar formation and its expression is inversely related to the periods of vascularization and alveolarization in the developing lung. Hence the study of EMAP II could play a vital role in studying and devising appropriate therapeutics for diseases of aberrant lung development, such as BPD. |